As of 2025-12-17, the Relative Valuation of Kinnate Biopharma Inc (KNTE) is (57.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Kinnate Biopharma Inc based on Relative Valuation is -2251.6%.
The range of the Relative Valuation is (41.55) - (59.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.1x - 25.1x | 21.1x |
| Forward P/E multiples | 17.4x - 35.9x | 26.6x |
| Fair Price | (41.55) - (59.94) | (57.02) |
| Upside | -1668.1% - -2362.0% | -2251.6% |
| Date | P/E |